- Home
- URGN vs ALX Comparison
URGN vs ALX Comparison
Compare URGN & ALX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- URGN
- ALX
- Stock Information
- Founded
- URGN 2004
- ALX 1928
- Country
- URGN United States
- ALX United States
- Employees
- URGN N/A
- ALX N/A
- Industry
- URGN Biotechnology: Pharmaceutical Preparations
- ALX Real Estate Investment Trusts
- Sector
- URGN Health Care
- ALX Real Estate
- Exchange
- URGN Nasdaq
- ALX Nasdaq
- Market Cap
- URGN 1.1B
- ALX 1.2B
- IPO Year
- URGN 2017
- ALX N/A
- Fundamental
- Price
- URGN $27.39
- ALX $213.49
- Analyst Decision
- URGN Strong Buy
- ALX
- Analyst Count
- URGN 8
- ALX 0
- Target Price
- URGN $28.50
- ALX N/A
- AVG Volume (30 Days)
- URGN 1.4M
- ALX 54.6K
- Earning Date
- URGN 11-06-2025
- ALX 11-03-2025
- Dividend Yield
- URGN N/A
- ALX 8.44%
- EPS Growth
- URGN N/A
- ALX N/A
- EPS
- URGN N/A
- ALX 7.14
- Revenue
- URGN $96,516,000.00
- ALX $215,838,000.00
- Revenue This Year
- URGN $35.07
- ALX N/A
- Revenue Next Year
- URGN $117.83
- ALX N/A
- P/E Ratio
- URGN N/A
- ALX $29.51
- Revenue Growth
- URGN 8.00
- ALX N/A
- 52 Week Low
- URGN $3.42
- ALX $184.76
- 52 Week High
- URGN $27.98
- ALX $260.84
- Technical
- Relative Strength Index (RSI)
- URGN 74.68
- ALX 41.96
- Support Level
- URGN $24.69
- ALX $201.28
- Resistance Level
- URGN $26.28
- ALX $225.06
- Average True Range (ATR)
- URGN 1.87
- ALX 5.87
- MACD
- URGN 0.32
- ALX -0.79
- Stochastic Oscillator
- URGN 95.93
- ALX 36.65
About URGN UroGen Pharma Ltd.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.
About ALX Alexander's Inc.
Alexander's Inc is a real estate investment trust engaged in leasing, managing, developing and redeveloping its properties. It has six properties in the greater New York City metropolitan area. All of the revenues come from properties located in New York City which include revenues from leasing of space to tenants at their properties and revenues from parking and tenant services.